Amino-tetralin derivatives as muscarinic receptor antagonists

Compounds of Formula I:

• wherein:
• R1 is (C1-6)alkyl;
• R2 is halogen or —OR′;
• R3 is hydrogen or —OR′;
• R′ is hydrogen, (C1-6)alkyl, or SO2R″;
• R″ is (C1-6)alkyl, haloalkyl, aryl or heteroaryl, wherein said aryl or heteroaryl groups are optionally substituted with a group selected from (C16)alkyl, halo, haloalkyl, cyano, nitro, alkylsulfonyl, and alkylsulfonylamino;
• R4 is (i) (C1-6)alkyl, (ii) aryl, heterocyclyl, or heteroaryl, wherein said aryl, heterocyclyl or heteroaryl groups are optionally substituted with a group selected from (C1-6)alkyl, halo, haloalkyl, (C1-6)alkoxy, cyano, amino, mono- or di alkylamino, nitro, alkylsulfonyl, alkylcarbonyl, urea, alkylcarbonylamino, alkylsulfonylamino, alkylaminosulfonyl, alkoxycarbonyl, heterocyclyl and heteroaryl, or (iii) —NR5R6;
• and
• R5 and R6 are independently of each other hydrogen, (C1-6)alkyl, aryl or heterocyclyl;
• wherein said aryl or heterocyclyl groups are optionally substituted with (C1-6)alkyl, halo, haloalkyl, cyano, (C1-6)alkoxy, and alkylsulfonyl;
• or an individual isomer, a racemic or non-racemic mixture of isomers, or an acceptable salt or solvate thereof.